Beta-2 agonists and exercise performance in humans;Bêta-2 agonistes et performance sportive

Science and Sports

Volumn 25, Issue 6, 2010, Pages 281-290

  Collomp, K ^a,b,c   Le Panse, B ^a   Candau, R ^d   Lecoq, A M ^a,e   De Ceaurriz, J ^b  

^a UNIVERSITÉ D'ORLÉANS   (France)

^b Agence Francaise de Lutte contre le Dopage   (France)

^c Universite Paris Sud   (France)

^d University of Montpellier   (France)

^e CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

Author keywords

Acute administration; Albuterol; Doping; Inhalation; Oral intake; Short term administration

Indexed keywords

ADRENALIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; CLENBUTEROL; FORMOTEROL; GENERIC DRUG; GLUCOSE; INSULIN; METHYLXANTHINE; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE;

ACUTE DRUG ADMINISTRATION; ASTHMA; ATHLETIC PERFORMANCE; BRONCHOSPASM; DOPING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; ENDURANCE TRAINING; ENERGY COST; EXERCISE; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCOGENOLYSIS; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LIOTHYRONINE BLOOD LEVEL; LOW DRUG DOSE; MAINTENANCE THERAPY; MUSCLE TRAINING; OUTCOME ASSESSMENT; OXIDATION; POTASSIUM BLOOD LEVEL; PREMATURE LABOR; PRIORITY JOURNAL; RESISTANCE TRAINING; SHORT COURSE THERAPY; SHORT SURVEY; SIDE EFFECT; TACHYCARDIA; WADA TEST;

EID: 78651486072     PISSN: 07651597     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.scispo.2010.08.002     Document Type: Short Survey

References (62)

1. Kindermann W., Meyer T. Inhaled beta 2-agonists and performance in competitive athletes. Br J Sports Med 2006, 40(Suppl. 1):43-47.
2. Kindermann W. Do inhaled beta(2)-agonists have an ergogenic potential in non-asthmatic competitive athletes?. Sports Med 2007, 37:95-102.
3. Lefkowitz R., de Lean A., Hoffmann B., Stadel J., Kent R. Molecular pharmacology of adenylate cyclise coupled- and β-adrenergic receptors. Adv Cyclic Nucleotide Res 1981, 14:145-161.
4. Price A., Clissold S. Salbutamol in the 1980s. A reappraisal of its clinical efficacy. Drugs 1989, 38:77-122.
5. Gummerus M. Best criterion for the assessment of efficacy of tocolysis and choice of most suitable betasympathomimetic. Acta Obstet Gynecol Scand 1985, 64:561-565.
6. Petersen R., Agertoft L., Pedersen S. Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma. Eur Respir J 2004, 24:932-937.
7. Conolly M., Tashkin D., Hui K., Littner M., Wolfe R. Selective subsensitization of beta-adrenergic receptors in central airways of asthmatics and normal subjects during long term therapy with inhaled salbutamol. J Allergy Clin Immunol 1982, 70:423-431.
8. Grove A., Lipworth B. Tolerance with beta2-adrenoceptor agonists: time for reappraisal. Br J Clin Pharmacol 1995, 39:109-118.
9. Tsanakas J., Bannister O., Baxter P. Tachyphylaxis does not occur after long-term administration of salbutamol controlled release (Volmax SCR). Eur Respiratory J 1988, Suppl. 2:202S.
10. Moore R., Khan A., Dickey B. Long-acting inhaled beta-2 agonists in asthma therapy. Chest 1998, 113:1095-1108.
11. Baker P., Dalrymple R., Ingle D., Ricks C. Use of an adrenergic agent to alter muscle and fat disposition in lambs. Fed Proc 1983, 42:816.
12. Beermann D., Butler W., Hogue D., Fishell V., Dalrymple R., Ricks C., et al. Cimaterol-induced muscle hypertrophy and altered endocrine status in lambs. J Anim Sci 1987, 65:1514-1524.
13. Carter W., Lynch M. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. Metabolism 1994, 43:1119-1125.
14. Reeds P., Hay S., Dorward P., Palmer R. The effects of β-agonists and antagonists on muscle growth and body composition of young rats. Comp Biochem Physiol 1988, 89:337-341.
15. Caruso J., Signorile J., Perry A., Leblanc B., Williams R., Clark M., et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc 1995, 27:1471-1476.
16. Martineau L., Horan M., Rothwell N., Little R., Salbutamol a β2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci 1992, 83:615-621.
17. 2-adrenoceptor agonist salmeterol are dependent on route of administration. Am J Physiol 1994, 30:E475-484.
18. Caruso J., Hamill J., De Garmo N. Oral albuterol dosing during the latter stages of a resistance exercise program. J Strength Cond Res 2005, 19:102-107.
19. Caruso J., Hamill J., Yamauchi M., Saito K., Cook T., Mercado D. Temporal strength changes from resistance exercise and albuterol on unloaded muscle. J Strength Cond Res 2008, 22:1156-1163.
20. Le Panse B., Collomp K., Portier H., Lecoq A.M., Jaffre C., Beaupied H., et al. Effects of short-term salbutamol ingestion during a Wingate test. Int J Sports Med 2005, 26:518-523.
21. Le Panse B., Arlettaz A., Portier H., Lecoq A.M., De Ceaurriz J., Collomp K. Short term salbutamol ingestion and supramaximal exercise in healthy women. Br J Sports Med 2006, 40:627-631.
22. Decorte N., Verges S., Flore P., Guinot M., Wuyam B. Effects of acute salbutamol inhalation on quadriceps force and fatigability. Med Sci Sports Exerc 2008, 40:1220-1227.
23. Goubault C., Perault M.C., Leleu E., Bouquet S., Legros P., Vandel B., et al. Effects of inhaled salbutamol ingestion in exercising non-asthmatic athletes. Thorax 2001, 56:675-679.
24. Sporer B., Sheel A., McKenzie D. Dose response of inhaled salbutamol on exercise performance and urine concentrations. Med Sci Sports Exerc 2008, 40:149-157.
25. Van Baak M., de Hon O., Hartgens F., Kuipers H. Inhaled salbutamol and endurance cycling performance in non-asthmatic athletes. Int J Sports Med 2004, 25:533-538.
26. Bedi J., Gong H., Horvath S. Enhancement of exercise performance with inhaled albuterol. Can J Sport Sci 1988, 13:144-148.
27. Carlsen K., Ingjer F., Kirkegaard H., Thyness B. The effect of inhaled salbutamol and salmeterol on lung function and endurance performance in healthy well-trained athletes. Scand J Med Sci Sports 1997, 7:160-165.
28. 2 and blood lactate. Int J Sports Med 1993, 14:239-243.
29. Gong H., Bedi J., Horvath S. Inhaled albuterol does not protect against ozone toxicity in nonasthmatic athletes. Arch Environ Health 1988, 43:46-53.
30. Heir T., Stemshaus H. Salbutamol and high-intensity treadmill running in non-asthmatic highly conditioned athletes. Scand J Med Sci Sports 1995, 5:231-236.
31. Lemmer J., Fleck S., Wallach J. The effects of albuterol on power output in nonasthmatic athletes. Int J Sports Med 1995, 16:243-249.
32. McKenzie S., Rhodes E., Stirling D., Wiley J., Dunwoody D., Filsinger I. Salbutamol and treadmill performance in non-atopic athletes. Med Sci Sports Exerc 1983, 15:520-522.
33. Meeuwisse W., McKenzie D., Hopkins S., Road J. The effect of salbutamol on performance in elite nonasthmatic athletes. Med Sci Sports Exerc 1992, 24:1161-1166.
34. Norris S., Peterson S., Jones R. The effect of salbutamol on performance in endurance cyclists. Eur J Appl Physiol Occup Physiol 1996, 73:364-368.
35. Sandsund M., Sue-Chu J., Helgerud R., Reinertsen I., Bjermer L. Effect of cold exposure (-15°C) and salbutamol treatment on physical treatment on physical performance in elite nonasthmatic cross-country skiers. Eur J Appl Physiol 1998, 77:297-304.
36. Signorile J., Kaplan J., Applegate B., Perry A. Effect of acute inhalation of the bronchodilatator, albuterol, on power output. Med Sci Sports Exerc 1992, 24:638-642.
37. 2-agonist on physical performance at low temperature in elite athletes. Med Sci Sports Exerc 1997, 29:1631-1636.
38. McDowell S., Fleck S., Storms W. The effects of salmeterol on power output in nonasthmatic athletes. J Allergy Clin Immunol 1997, 99:443-449.
39. Morton A., Jovce K., Papalia S., Carroll N., Fitch K. Is salmeterol ergogenic?. Clin J Sport Med 1996, 6:220-225.
40. Sue-Chu M., Sandsund M., Helgerud J., Reinertsen R., Bjermer L. Salmeterol and physical performance at -15 degrees C in highly trained nonasthmatic cross-country skiers. Scand J Med Sci Sports 1999, 9:48-52.
41. Carlsen K., Hem E., Stensrud T., Held T., Herland K., Mowinckel P. Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta-2 agonist formoterol upon endurance performance in healthy well-trained athletes. Respir Med 2001, 95:571-576.
42. Riiser A., Tjorhom A., Carlsen K. The effect of formoterol inhalation on endurance performance in hypobaric conditions. Med Sci Sport Exerc 2006, 38:2132-2137.
43. Stewart I., Labreche J., McKenzie D. Acute formoterol administration has no ergogenic effect in nonasthmatic athletes. Med Sci Sports Exerc 2002, 34:213-217.
44. Tjorhom A., Riiser A., Carlsen K. Effects of formoterol on endurance performance in athletes at an ambient temperature of -20 degrees C. Scand J Med Sci Sports 2007, 17:628-635.
45. Van Baak M., Mayer L., Kempinski R., Hartgens F. Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men. Med Sci Sports Exerc 2000, 32:1300-1306.
46. Collomp K., Candau R., Collomp R., Carra J., Lasne F., Préfaut C., et al. Effects of acute ingestion of salbutamol during submaximal exercise. Int J Sports Med 2000, 21:480-484.
47. Collomp K., Candau R., Millet G., Mucci P., Borrani F., Préfaut C., et al. Effects of salbutamol and caffeine ingestion on exercise metabolism and performance. Int J Sports Med 2002, 23:549-554.
48. Collomp K., Le Panse B., Portier H., Lecoq A.M., Jaffre C., Richard O., et al. Effects of acute salbutamol intake during a Wingate test. Int J Sports Med 2005, 26:513-517.
49. Le Panse B., Arlettaz A., Portier H., Lecoq A.M., De Ceaurriz J., Collomp K. Effects of acute salbutamol intake during supramaximal exercise in women. Br J Sports Med 2007, 41:430-434.
50. Collomp K., Candau R., Lasne F., Labsy Z., Préfaut Ch, De Ceaurriz J. Effects of short-term oral salbutamol administration on exercise endurance and metabolism. J Appl Physiol 2000, 89:430-436.
51. Caruso J., Hamill J., Yamauchi M., Mercado D., Cook T., Higginson B., et al. Albuterol aids resistance exercise in reducing unloading-induced ankle extensor strength losses. J Appl Physiol 2005, 98:1705-1711.
52. Kendall M., Clark N., Haffner C., Kong J., Hughes B. Investigation of the effects of beta-2 stimulation on free fatty acids in man. J Clin Pharm Ther 1991, 16:31-40.
53. Rizza R., Cryer P., Haymond M., Gerich J. Adrenergic mechanisms of catecholamine action on glucose homeostasis in man. Metabolism 1980, 29:1155-1163.
54. Rolf Smith S., Kendall M. Metabolic responses to β2 stimulants. J R Coll Chest Physiol 1984, 18:190-194.
55. Schiffelers S., Brouwer E., Saris W., Van Baak M. Inhibition of lipolysis reduces beta1-adrenoceptor-mediated thermogenesis in man. Metabolism 1998, 47:1462-1467.
56. Schiffelers S., Saris W., Boomsma F., Van Baak M. Beta(1)- and beta(2)-adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men. J Clin Endocrinol Metab 2001, 86:2191-2199.
57. Arlettaz A., Le Panse B., Portier H., Lecoq A.-M., Thomasson R., De Ceaurriz J., et al. Salbutamol intake and substrate oxidation during submaximal exercise. Eur J Appl Physiol 2009, 105:207-213.
58. Wager J., Fredholm B., Lunell N., Persson B. Metabolic and circulatory effects of intravenous and oral salbutamol in late pregnancy in diabetic and non diabetic women. Acta Obstet Gynecol Scand 1982, 108:41-46.
59. 2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis. J Endocrinol Invest 1995, 18:847-852.
60. Lindinger M., Graham T., Spriet L. Caffeine attenuates the exercise-induced increase in plasma [K+] in humans. J Appl Physiol 1993, 74:1149-1155.
61. + from muscle during prolonged dynamic exercise. Acta Physiol Scand 1989, 136:293-294.
62. Sjogaard G., Adams R., Saltin B. Water and ion shifts in skeletal muscle of humans with intense dynamic knee extension. Am J Physiol 1985, 248:R190-196.